[HTML][HTML] Window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (SCCHN): Interim safety analysis
Background Despite the application of PD-1 inhibitors in clinical practice in SCCHN, only a
fraction of patients shows durable responses to monotherapy. Numerous combinatorial …
fraction of patients shows durable responses to monotherapy. Numerous combinatorial …
Window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (SCCHN): Interim safety analysis
T Richa, JM Johnson, DM Cognetti… - Annals of …, 2019 - annalsofoncology.org
Background Despite the application of PD-1 inhibitors in clinical practice in SCCHN, only a
fraction of patients shows durable responses to monotherapy. Numerous combinatorial …
fraction of patients shows durable responses to monotherapy. Numerous combinatorial …